MT-0169 is an investigative therapy that contains an antibody fragment targeting CD38 (a protein found in high levels on the surface of myeloma cells. It is fused to a Shiga-like toxin A-subunit (SLTA), a bacterial protein that, once inside malignant myeloma cells, irreversibly blocks the protein-making machinery of the cell and kills it.
| SparkCures ID | 352 |
|---|---|
| Developed By | Molecular Templates |
| Generic Name | MT-0169 |
| Treatment Classifications |
|
| Treatment Targets |